CTI BioPharma Corp. (NASDAQ:CTIC – Get Rating) – Analysts at SVB Leerink upped their Q2 2023 earnings per share estimates for shares of CTI BioPharma in a research report issued on Monday, May 15th. SVB Leerink analyst K. Shields now forecasts that the biopharmaceutical company will earn ($0.08) per share for the quarter, up from […]
CTI BioPharma (NASDAQ:CTIC – Get Rating) was downgraded by equities researchers at Stifel Nicolaus from a “buy” rating to a “hold” rating in a note issued to investors on Monday, The Fly reports. Other research analysts have also issued research reports about the stock. TD Cowen decreased their price target on shares of CTI BioPharma […]
CTI BioPharma Corp. (NASDAQ:CTIC – Get Rating) has been assigned a consensus recommendation of “Moderate Buy” from the ten research firms that are covering the company, MarketBeat reports. Five analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month target price among brokers […]
CTI BioPharma Corp. (NASDAQ:CTIC – Get Rating) was the recipient of a significant drop in short interest in April. As of April 30th, there was short interest totalling 12,170,000 shares, a drop of 24.2% from the April 15th total of 16,050,000 shares. Based on an average trading volume of 3,010,000 shares, the days-to-cover ratio is […]
JMP Securities lowered shares of CTI BioPharma (NASDAQ:CTIC – Get Rating) from an outperform rating to a market perform rating in a research note issued to investors on Thursday, The Fly reports. Several other equities research analysts have also recently issued reports on the stock. StockNews.com raised shares of CTI BioPharma from a sell rating […]